Announcement on Subsidiary HB0025 Injection Initiating Phase III Clinical Trial

About this update from Zhejiang Huahai Pharmaceutical Co., Ltd. Class A

Announcement on Subsidiary HB0025 Injection Initiating Phase III Clinical Trial The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Zhejiang Huahai Pharmaceutical Co., Ltd. Class A